Antidiabetic Tenelia market rises 67% with entry of generics
By Kim, Jin-Gu | translator Kim, Jung-Ju
23.04.27 06:20:53
가나다라
0
Prescription of Tenelia generics in Q1 record KRW 8.4 billion... market share rises 41% in 5 months
Original’s sales fall slightly from KRW 12.3 billion to KRW 12 billion...Januvia and other top-grossing products suffer a blow
The teneligliptin antidiabetic market has expanded 1.7 times in a single year. This is analyzed to be influenced by the large amount of generics that entered the market in October last year.
Only 5 months after its launch, prescriptions of Tenelia generics that were launched exceeded KRW 10 billion, and their market share grew to 41%.
◆ Tenelia generics Market share increased to 41%…most products sell less than KRW 300 million
According to the market research institution UBIST, outpatient prescriptions of the teneligliptin antidiabetic drugs market rose to reach KRW 20.5 billion in Q1. This is a 67% market increase from KRW 12.3 billion in Q1 2022.
Th
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)